Efflux pump gene amplifications bypass necessity of multiple target mutations for resistance against dual-targeting antibiotic
暂无分享,去创建一个
[1] J. Heddle,et al. Gene amplifications cause high-level resistance against albicidin in Gram-negative bacteria , 2022, bioRxiv.
[2] W. Roos,et al. Teixobactin kills bacteria by a two-pronged attack on the cell envelope , 2022, Nature.
[3] S. Satola,et al. Heteroresistance via beta-lactamase gene amplification threatens the beta-lactam pipeline , 2022, bioRxiv.
[4] Ying Li,et al. Discovering interrelated natural mutations of efflux pump KmrA from Klebsiella pneumoniae that confer increased multidrug resistance , 2022, Protein science : a publication of the Protein Society.
[5] M. Bhattacharyya,et al. Efflux-linked Accelerated Evolution of Antibiotic Resistance at a Population Edge , 2022, bioRxiv.
[6] Alan D. Lopez,et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis , 2022, The Lancet.
[7] D. Hassabis,et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models , 2021, Nucleic Acids Res..
[8] Melissa H. Brown,et al. Efflux Pump Mediated Antimicrobial Resistance by Staphylococci in Health-Related Environments: Challenges and the Quest for Inhibition , 2021, Antibiotics.
[9] Oriol Vinyals,et al. Highly accurate protein structure prediction with AlphaFold , 2021, Nature.
[10] Nadezhda T. Doncheva,et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..
[11] C. Pál,et al. Rational design of balanced dual-targeting antibiotics with limited resistance , 2020, PLoS biology.
[12] R. MacLean,et al. Efflux pump activity potentiates the evolution of antibiotic resistance across S. aureus isolates , 2020, Nature Communications.
[13] W. Shafer,et al. Cryo-EM Structures of a Gonococcal Multidrug Efflux Pump Illuminate a Mechanism of Drug Recognition and Resistance , 2020, mBio.
[14] Maxwell Z. Wilson,et al. A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance , 2020, Cell.
[15] Prabasaj Paul,et al. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. , 2020, The New England journal of medicine.
[16] Narmada Thanki,et al. CDD/SPARCLE: the conserved domain database in 2020 , 2019, Nucleic Acids Res..
[17] D. Landman,et al. Emergence of Delafloxacin-Resistant Staphylococcus aureus in Brooklyn, NY. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] D. Andersson,et al. Mechanisms and clinical relevance of bacterial heteroresistance , 2019, Nature Reviews Microbiology.
[19] Christian Lesterlin,et al. Role of AcrAB-TolC multidrug efflux pump in drug-resistance acquisition by plasmid transfer , 2019, Science.
[20] Sophie A Howard,et al. Use of the counter selectable marker PheS* for genome engineering in Staphylococcus aureus. , 2019, Microbiology.
[21] M. Vestergaard,et al. Antibiotic Resistance and the MRSA Problem , 2019, Microbiology spectrum.
[22] B. Levin,et al. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification , 2019, Nature Microbiology.
[23] G. Stein,et al. Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] E. Peterson,et al. Antibiotic Resistance Mechanisms in Bacteria: Relationships Between Resistance Determinants of Antibiotic Producers, Environmental Bacteria, and Clinical Pathogens , 2018, Front. Microbiol..
[25] M. Dunlop,et al. Heterogeneity in efflux pump expression predisposes antibiotic-resistant cells to mutation , 2018, Science.
[26] B. Luisi,et al. Multidrug efflux pumps: structure, function and regulation , 2018, Nature Reviews Microbiology.
[27] T. Park,et al. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa , 2018, Expert review of anti-infective therapy.
[28] W. Reygaert. An overview of the antimicrobial resistance mechanisms of bacteria , 2018, AIMS microbiology.
[29] Jia Gu,et al. fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.
[30] Jones K. Adjei,et al. Modulation of antimicrobial efflux pumps of the major facilitator superfamily in Staphylococcus aureus , 2018, AIMS microbiology.
[31] A. Oliver,et al. Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone , 2017, Scientific Reports.
[32] D. Doyle,et al. Efflux drug transporters at the forefront of antimicrobial resistance , 2017, European Biophysics Journal.
[33] Q. C. Truong-Bolduc,et al. Transcriptional Regulator TetR21 Controls the Expression of the Staphylococcus aureus LmrS Efflux Pump , 2017, Antimicrobial Agents and Chemotherapy.
[34] F. J. Candel,et al. Delafloxacin: design, development and potential place in therapy , 2017, Drug design, development and therapy.
[35] P. Hall,et al. Generation of a Stable Plasmid for In Vitro and In Vivo Studies of Staphylococcus Species , 2016, Applied and Environmental Microbiology.
[36] Saeed Tavazoie,et al. Multifactorial Competition and Resistance in a Two-Species Bacterial System , 2015, PLoS genetics.
[37] T. Foster,et al. Erratum for Monk et al., Complete Bypass of Restriction Systems for Major Staphylococcus aureus Lineages , 2016, mBio.
[38] A. Ivens,et al. A Novel Gene Amplification Causes Upregulation of the PatAB ABC Transporter and Fluoroquinolone Resistance in Streptococcus pneumoniae , 2015, Antimicrobial Agents and Chemotherapy.
[39] Jun Lin,et al. Mechanisms of antibiotic resistance , 2015, Front. Microbiol..
[40] K. Lewis,et al. A new antibiotic kills pathogens without detectable resistance , 2015, Nature.
[41] E. Oldfield,et al. Resistance-resistant antibiotics. , 2014, Trends in pharmacological sciences.
[42] P. Tulkens,et al. Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from Staphylococcus aureus Clinical Isolates , 2014, Antimicrobial Agents and Chemotherapy.
[43] L. Piddock,et al. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. , 2014, Trends in microbiology.
[44] Björn Usadel,et al. Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..
[45] Jeffrey E. Barrick,et al. Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. , 2014, Methods in molecular biology.
[46] T. S. McConnell,et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. , 2012, The Journal of antimicrobial chemotherapy.
[47] L. Fernández,et al. Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance , 2012, Clinical Microbiology Reviews.
[48] S. V. van Hal,et al. Predictors of Mortality in Staphylococcus aureus Bacteremia , 2012, Clinical Microbiology Reviews.
[49] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[50] Sanath H. Kumar,et al. LmrS Is a Multidrug Efflux Pump of the Major Facilitator Superfamily from Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.
[51] A. Kwon,et al. Extended Spectrum of Quinolone Resistance, Even to a Potential Latter Third-Generation Agent, as a Result of a Minimum of Two GrlA and Two GyrA Alterations in Quinolone-Resistant Staphylococcus aureus , 2010, Chemotherapy.
[52] Diarmaid Hughes,et al. Gene amplification and adaptive evolution in bacteria. , 2009, Annual review of genetics.
[53] Linus Sandegren,et al. Bacterial gene amplification: implications for the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.
[54] H. Boucher,et al. Epidemiology of methicillin-resistant Staphylococcus aureus. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[55] Roberta B Carey,et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.
[56] I. Chopra,et al. Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies. , 2007, The Journal of antimicrobial chemotherapy.
[57] R. Birch,et al. The Phytotoxin Albicidin is a Novel Inhibitor of DNA Gyrase , 2007, Antimicrobial Agents and Chemotherapy.
[58] D. Albertson,et al. Gene amplification in cancer. , 2006, Trends in genetics : TIG.
[59] T. Tsuchiya,et al. Gene cloning and characterization of SdrM, a chromosomally-encoded multidrug efflux pump, from Staphylococcus aureus. , 2006, Biological & pharmaceutical bulletin.
[60] M. Sasatsu,et al. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. , 2005, International journal of antimicrobial agents.
[61] Angela M. Nilius,et al. In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone , 2003, Antimicrobial Agents and Chemotherapy.
[62] D. Ince,et al. Topoisomerase Targeting with and Resistance to Gemifloxacin in Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.
[63] M. Sasatsu,et al. Cloning and characterization of a novel chromosomal drug efflux gene in Staphylococcus aureus. , 2002, Biological & pharmaceutical bulletin.
[64] D. Ince,et al. Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone , 2002, Antimicrobial Agents and Chemotherapy.
[65] R. Lambert,et al. Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non‐inhibitory concentration (NIC) values , 2000, Journal of applied microbiology.
[66] K. Drlica,et al. Mechanism of fluoroquinolone action. , 1999, Current opinion in microbiology.
[67] H. Hiasa,et al. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. , 1998, Biochimica et biophysica acta.
[68] K. Köhrer,et al. Characterization of grlA, grlB, gyrA, and gyrB Mutations in 116 Unrelated Isolates of Staphylococcus aureus and Effects of Mutations on Ciprofloxacin MIC , 1998, Antimicrobial Agents and Chemotherapy.
[69] K. Hiramatsu,et al. A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. , 1990, Biochemical and biophysical research communications.
[70] Jacques Monod,et al. The genetic control and cytoplasmic expression of “Inducibility” in the synthesis of β-galactosidase by E. coli , 1959 .